News briefing: Locus Biosciences bags up to $12.1M for CRISPR antibacterial; Old Vertex drug heads to PhIII for dementia
In its latest effort to spur the development of new antibacterial drugs, the non-profit CARB-X is awarding Locus Biosciences up to $12.1 million for its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
